14th World Conference on Lung Cancer - reviewed by A/Prof Paul Mitchell

In this review:

MetMab + erolinib in advanced NSCLC
Erlotinib benefits EGFR-mutant Caucasians
Denosumab improves survival in lung cancer
Amrubicin in 2nd-line treatment of SCLC
Cisplatin dose in advanced NSCLC
Optimising first-line CT plus cetuximab
Continued pemetrexed

Please login below to download this issue (PDF)